Holzgreve W, Di Naro E, Garvin A M, Troeger C, Hahn S
Department of Obstetrics and Gynecology, University of Basel, Schanzenstrasse 46, Basel, 4031, Switzerland.
Croat Med J. 1998 Jun;39(2):115-20.
The ability to use fetal cells enriched from the blood of pregnant women for prenatal diagnosis has been a long-sought goal for those pursuing a non-invasive alternative to current methods, such as amniocentesis or chorionic villus sampling. Several new developments, which rely either on fluorescence in situ hybridization or the combination of single-cell manipulation and subsequent polymerase chain reaction practices, which are common to the field of preimplantation genetics, have been tested. We discuss the significance of these developments and the obstacles that still have to be surmounted before this technology becomes available in a broad diagnostic use. The research in the field yielded important observations regarding the traffic of cells between the fetus and the mother, which may provide a new insight into the development of disorders such as preeclampsia and the associated HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome.
对于那些寻求替代当前侵入性方法（如羊膜穿刺术或绒毛取样）进行产前诊断的无创方法的人来说，利用从孕妇血液中富集的胎儿细胞进行产前诊断的能力一直是他们长期追求的目标。人们已经测试了几种新的技术，这些技术要么依赖于荧光原位杂交，要么依赖于单细胞操作与后续聚合酶链反应技术的结合，这些技术在植入前遗传学领域很常见。我们讨论了这些技术进展的意义，以及在这项技术广泛应用于诊断之前仍需克服的障碍。该领域的研究得出了关于胎儿与母亲之间细胞交换的重要观察结果，这可能为诸如先兆子痫和相关的HELLP（溶血、肝酶升高、血小板减少）综合征等疾病的发展提供新的见解。
